...four. Patients receive subcutaneous Tremfya at weeks zero and four, and then every eight weeks. Sun Pharma...

...least two other companies have inhibitors of ABL proteins in development for PD. In August Sun Pharma Advanced Research Company Ltd....
...Inhibikase Therapeutics Inc., Atlanta, Ga. Neuraly Inc., Baltimore, Md. Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland Sun Pharma Advanced Research Company Ltd....

...J&J also markets Stelara ustekinumab to treat psoriasis. That drug targets both IL-23 and IL-12. Sun Pharma...

...BLA. J&J's approved psoriasis drug Stelara ustekinumab targets both IL-23 and IL-12 . On Friday, Sun Pharma...

...the EU, to treat basal cell carcinoma (BCC). Novartis declined to disclose financial terms, and Sun Pharma...

...Rates for the high dose were 36% at week 12 and 59% at week 28. Sun Pharma...

...Sun Pharma Advanced Research Co. (SPARC) granted Sun Pharma U.S. rights to Elepsia XR levetiracetam, an extended-release...
...September complete response letter citing manufacturing compliance issues. The companies did not respond to inquiries. Sun Pharma Advanced Research Company Ltd....

...AstraZeneca granted Sun Pharma rights to commercialize diabetes drug dapagliflozin in India under the brand name Oxra...